The closing price of CureVac N.V. (NASDAQ: CVAC) was $2.88 for the day, down -3.36% from the previous closing price of $2.98. In other words, the price has decreased by -$0.1000 from its previous closing price. On the day, 637494 shares were traded.
Ratios:
Our analysis of CVAC’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.41 and its Current Ratio is at 3.56. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, SVB Securities on June 08, 2023, initiated with a Outperform rating and assigned the stock a target price of $13.
On January 19, 2023, UBS Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $8 to $18.
Jefferies Upgraded its Hold to Buy on January 09, 2023, whereas the target price for the stock was revised from $9 to $21.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CVAC now has a Market Capitalization of 642.66M and an Enterprise Value of 183.47M. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.09 while its Price-to-Book (P/B) ratio in mrq is 1.01. Its current Enterprise Value per Revenue stands at 4.28 whereas that against EBITDA is -0.66.
Stock Price History:
Over the past 52 weeks, CVAC has reached a high of $12.36, while it has fallen to a 52-week low of $2.76. The 50-Day Moving Average of the stock is 3.3744, while the 200-Day Moving Average is calculated to be 6.2010.
Shares Statistics:
CVAC traded an average of 796.03K shares per day over the past three months and 628.61k shares per day over the past ten days. A total of 223.88M shares are outstanding, with a floating share count of 91.60M. Insiders hold about 59.08% of the company’s shares, while institutions hold 10.01% stake in the company. Shares short for CVAC as of Mar 15, 2024 were 4.86M with a Short Ratio of 6.10, compared to 4.26M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.17% and a Short% of Float of 12.22%.
Earnings Estimates
The firm’s stock currently is rated by 6 analysts. On average, analysts expect EPS of -$0.2 for the current quarter, with a high estimate of -$0.11 and a low estimate of -$0.33, while EPS last year was -$0.66. The consensus estimate for the next quarter is -$0.18, with high estimates of -$0.15 and low estimates of -$0.24.
Analysts are recommending an EPS of between -$0.9 and -$1.2 for the fiscal current year, implying an average EPS of -$1.03. EPS for the following year is -$0.98, with 9 analysts recommending between -$0.54 and -$1.41.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 7 analysts. It ranges from a high estimate of $77.7M to a low estimate of $20.28M. As of the current estimate, CureVac N.V.’s year-ago sales were $12.83M, an estimated increase of 183.80% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $16.2M, an increase of 12.00% less than the figure of $183.80% in the same quarter last year. There is a high estimate of $25.9M for the next quarter, whereas the lowest estimate is $8.66M.
